| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,857 |
| 52
Week Range: |
$37.29 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
230,132 |
422,694 |
1,171,108 |
1,389,174 |
| Total Sell Value |
$15,188,297 |
$25,482,465 |
$68,628,084 |
$77,001,153 |
| Total People Sold |
8 |
9 |
11 |
11 |
| Total Sell Transactions |
20 |
41 |
78 |
81 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Carey Stephen P. |
Vice President and CFO |
• – – |
2020-03-31 |
4 |
D |
$40.74 |
$20,655 |
D/D |
(507) |
23,990 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2020-03-28 |
4 |
D |
$37.76 |
$158,743 |
D/D |
(4,204) |
198,385 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2020-03-28 |
4 |
D |
$37.76 |
$39,157 |
D/D |
(1,037) |
54,890 |
|
- |
|
| Carey Stephen P. |
Vice President and CFO |
• – – |
2020-03-28 |
4 |
D |
$37.76 |
$35,985 |
D/D |
(953) |
24,497 |
|
- |
|
| Haughey Thomas |
Director |
– • – |
2020-03-04 |
4 |
B |
$45.05 |
$135,150 |
D/D |
3,000 |
11,291 |
2.39 |
-39% |
|
| Haughey Thomas |
Director |
– • – |
2020-03-03 |
4 |
B |
$45.18 |
$90,360 |
D/D |
2,000 |
8,291 |
2.39 |
-38% |
|
| Brown Robert E. Jr |
Director |
– • – |
2019-08-20 |
4/A |
AS |
$68.18 |
$375,808 |
D/D |
(5,512) |
2,281,283 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2019-08-20 |
4 |
AS |
$68.18 |
$375,808 |
D/D |
(5,512) |
2,219,259 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2019-08-19 |
4/A |
AS |
$68.30 |
$141,176 |
D/D |
(2,067) |
2,286,795 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2019-08-19 |
4 |
AS |
$68.30 |
$141,176 |
D/D |
(2,067) |
2,224,771 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2019-08-16 |
4 |
AS |
$68.09 |
$1,794,103 |
D/D |
(26,349) |
2,226,838 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2019-08-15 |
4 |
AS |
$69.34 |
$645,902 |
D/D |
(9,315) |
2,253,187 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2019-08-14 |
4 |
AS |
$69.89 |
$1,842,300 |
D/D |
(26,360) |
2,262,502 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2019-08-13 |
4 |
AS |
$71.77 |
$1,494,323 |
D/D |
(20,821) |
2,288,862 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2019-08-12 |
4 |
AS |
$71.45 |
$1,501,593 |
D/D |
(21,016) |
2,309,683 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2019-08-09 |
4 |
AS |
$71.70 |
$1,423,962 |
D/D |
(19,860) |
2,330,699 |
|
- |
|
| Nash David |
Director |
– • – |
2019-05-24 |
4 |
B |
$68.76 |
$99,358 |
D/D |
1,445 |
5,236 |
2.39 |
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2019-05-17 |
4 |
S |
$70.67 |
$629,458 |
D/D |
(8,907) |
61,230 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2019-05-16 |
4 |
OE |
$6.36 |
$45,138 |
D/D |
2,209 |
22,561 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2019-05-13 |
4 |
S |
$71.13 |
$171,352 |
D/D |
(2,409) |
55,927 |
|
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2019-04-16 |
4 |
D |
$68.60 |
$7,889 |
D/D |
(115) |
75,054 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2019-04-16 |
4 |
D |
$68.60 |
$24,696 |
D/D |
(360) |
58,336 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2019-04-16 |
4 |
D |
$68.60 |
$116,071 |
D/D |
(1,692) |
232,589 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2019-04-07 |
4 |
D |
$70.50 |
$27,636 |
D/D |
(392) |
58,696 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2019-04-07 |
4 |
D |
$70.50 |
$149,108 |
D/D |
(2,115) |
234,281 |
|
- |
|
399 Records found
|
|
Page 10 of 16 |
|
|
0.59 (0.89%) 
